![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Corthera, Inc. |
---|---|
Information provided by: | Corthera, Inc. |
ClinicalTrials.gov Identifier: | NCT00520806 |
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
Condition | Intervention | Phase |
---|---|---|
Heart Failure, Congestive |
Drug: Relaxin |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure |
Study Start Date: | October 2007 |
This is an international, randomized, double-blind, placebo-controlled trial of intravenous recombinant relaxin for the treatment of signs and symptoms in patients hospitalized for acute decompensated heart failure. A pilot study will determine the optimum dose of relaxin which will be studied further in the main portion of the trial.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sam Teichman, MD | 925.314.0569 |
United States, Illinois | |
Northwestern University | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Peter Pang | |
United States, Michigan | |
Wayne State University/Detroit Receiving Hospital | Recruiting |
Detroit, Michigan, United States, 48201 | |
Contact: Phillip Levy | |
United States, Ohio | |
University of Cincinnati College of Medicine | Recruiting |
Cincinnati, Ohio, United States, 45267 | |
Contact: Sean Collins | |
Israel | |
Heart Institute | Recruiting |
Safed, Israel |
Study Director: | Sam Teichman, MD | Corthera, Inc. |
Responsible Party: | Corthera, Inc. ( Sam Teichman, Chief Medical Officer ) |
Study ID Numbers: | RLX.CHF.003 |
Study First Received: | August 24, 2007 |
Last Updated: | April 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00520806 History of Changes |
Health Authority: | United States: Food and Drug Administration; Israel: Ministry of Health |
Heart failure Renal dysfunction Relaxin Vasodilator |
Vasodilator Agents Heart Failure Heart Diseases |
Muscle Relaxants, Central Methocarbamol Peripheral Nervous System Agents |
Heart Failure Heart Diseases Therapeutic Uses Muscle Relaxants, Central Methocarbamol Physiological Effects of Drugs |
Neuromuscular Agents Cardiovascular Diseases Peripheral Nervous System Agents Central Nervous System Agents Pharmacologic Actions |